Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01. (April 2017)

• Record Type: Journal Article
• Authors: Kay, Lara; Willems, Laurent M.; Zöllner, Johann Philipp; Reif, Philipp S.; Klein, Karl Martin; Rosenow, Felix; Strzelczyk, Adam
• Is Part Of: Seizure. Volume 47(2017)
• Page Start: 81
• Page End: 82
• Publication Date: 2017-04
• Subjects: Skin reaction -- Allergic -- HLA-B*1502 -- Carbamazepine epoxide; Epilepsy -- Periodicals; Epilepsy -- Periodicals; Seizures -- Periodicals; Épilepsie -- Périodiques; Electronic journals; Electronic journals; 616.853
• DOI: 10.1016/j.seizure.2017.02.019
• Languages: English
• ISSNs: 1059-1311

Abstract

Abstract: Eslicarbazepine acetate (ESL) is an anticonvulsant drug approved for the treatment of focal epilepsies, and related to oxcarbazepine and carbamazepine (CBZ), which are also derivatives of the dibenzazepine family. ESL is contraindicated in patients with hypersensitivity reactions to CBZ.We report a patient with frontal lobe epilepsy responding to treatment with ESL without any serious adverse effects after developing a severe skin rash following treatment with CBZ. HLA testing revealed an HLA-A*31:01 haplotype, that increases the risk of CBZ-induced cutaneous reactions.This case study shows that, in clinical practice, ESL may be considered in a patient with the HLA-A*31:01 haplotype and a hypersensitivity reaction to CBZ.